Company Highlights - Wellgistics Health, Inc. (NASDAQ:WGRX) experienced a significant price increase of 168.16%, reaching $1.08, driven by its blockchain initiative in prescription drug tracking [1][5] - MaxsMaking Inc. (NASDAQ:MAMK) saw its stock price rise by 148.70% to $7.43, following a successful IPO that raised $6.5 million, indicating strong investor interest in its innovative textile production [1][5] - Inhibrx Biosciences, Inc. (NASDAQ:INBX) reported a stock price surge of 94.43% to $55.13, likely due to positive developments in its clinical trials for a rare bone cancer treatment [2][5] - Genenta Science S.p.A. (NASDAQ:GNTA) experienced a 92.72% increase in stock price to $6.22, attributed to promising clinical trial results and a strategic partnership with ANEMOCYTE [3] Market Dynamics - The significant price movements across these companies reflect diverse investor interest in sectors such as healthcare, biotechnology, and consumer goods, influenced by clinical trial outcomes, strategic partnerships, and innovative product offerings [4]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Insights - The article discusses Inhibrx Biosciences, Inc. (NASDAQ: INBX) and its recent developments, particularly following the sale of INBRX-101 to Sanofi [2]. Company Overview - Inhibrx Biosciences is highlighted for its continued advancement in the biotech sector, indicating a positive trajectory despite the sale of a key asset [2]. Investment Analysis - The author operates a service called Biotech Analysis Central, which provides in-depth analysis of various pharmaceutical companies, including a model portfolio of small and mid-cap stocks [2].

At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading highe ...

Inhibrx Biosciences Inc. (NASDAQ:INBX) shares rose 75.95% in after-hours trading on Thursday, closing at $49.90.Check out the current price of INBX stock here. According to Benzinga Pro data, the stock closed regular trading at $28.36, down 10.03%.ChonDRAgon Study Results AnnouncedOn Thursday, the California-based clinical-stage biopharmaceutical company announced positive topline results from the registrational ChonDRAgon study, a Phase 2 trial evaluating ozekibart (INBRX-109) as a single agent versus plac ...

Biotech stocks led the after-hours charge on Thursday, with Inhibrx Biosciences (INBX) skyrocketing over 81% on positive Phase 2 trial results in chondrosarcoma. Femasys (FEMY), Cingulate (CING), and Community Health Systems (CYH) also posted notable gains, driven by clinical milestones and upbeat earnings. Here's a look at the top post-market movers.Shares of Inhibrx Biosciences Inc. (INBX) surged over 81% at $51.52 in after-hours trading, propelled by positive topline results from its registrational Chon ...

Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer in a mid-stage trial, sending its shares surging over 70% in extended tradin... ...

Core Insights - Inhibrx Biosciences announced positive topline results from the ChonDRAgon study, demonstrating the efficacy of ozekibart (INBRX-109) in treating advanced or metastatic chondrosarcoma, achieving a statistically significant improvement in median progression-free survival (PFS) compared to placebo [1][2][6] Chondrosarcoma Study Results - The ChonDRAgon study met its primary endpoint, showing a 52% reduction in the risk of disease progression or death with ozekibart, resulting in a median PFS of 5.52 months versus 2.66 months for placebo [2][6] - Ozekibart is the first investigational therapy to show a significant PFS benefit in a randomized trial for chondrosarcoma, a condition lacking approved systemic treatments [2][6] - Key secondary endpoints indicated a disease control rate of 54% for ozekibart compared to 27.5% for placebo, along with improvements in pain and physical function [3][6] Safety Profile - Ozekibart was generally well tolerated, with common treatment-related adverse events including fatigue, constipation, and nausea. The incidence of treatment-related hepatic adverse events was 11.8% compared to 4.5% in the placebo group [4][10] - Hepatotoxicity was managed effectively through patient selection and monitoring, resulting in a low overall incidence of severe liver-related adverse events [4][10] Expansion Cohorts - Inhibrx is conducting expansion cohorts for ozekibart in combination with FOLFIRI for colorectal cancer and with irinotecan and temozolomide for Ewing sarcoma, showing promising early results [6][15] - Initial results from the colorectal cancer trial indicated a 23% overall response rate and a 92% disease control rate in a heavily pretreated patient population [7][8] - For Ewing sarcoma, the combination therapy showed a 64% overall response rate and a 92% disease control rate among evaluable patients [9][10] Future Plans - The company plans to file a Biologics License Application (BLA) for ozekibart in Q2 of 2026, aiming to expedite its availability to patients [6][10] - Detailed results from the ChonDRAgon study will be presented at the Connective Tissue Oncology Society Annual Meeting on November 14, 2025 [5][6]

Core Insights - Biotech stocks experienced significant gains in after-hours trading on October 22, 2023, primarily driven by Ventyx Biosciences' positive Phase 2 data, which led to an 88% surge in its stock price [1][2]. Company Performance - Ventyx Biosciences Inc. (VTYX) saw its shares increase by over 88% following the announcement of positive results from its Phase 2 study of VTX3232 for patients with obesity and cardiovascular risk factors [2]. - Medpace Holdings, Inc. (MEDP) reported better-than-expected Q3 results, resulting in an over 18% increase in its stock price during after-hours trading [2]. - Inhibrx Biosciences Inc. (INBX) shares rose over 10% to $34.98 after announcing a live webcast presentation to discuss topline results from the ChonDRAgon study [3]. - SCYNEXIS Inc. (SCYX) shares increased by over 11% to $0.87 [4]. - Acumen Pharmaceuticals Inc. (ABOS) experienced a notable rise of over 24.9% to $2.31 [4]. - Rani Therapeutics Holdings Inc. (RANI) shares were up over 9% at $2.64 [4]. - iBio Inc. (IBIO) shares increased by over 7% to $1.50 [4]. - Chemomab Therapeutics Ltd. (CMMB) shares rose over 7% to $3.32 [4]. - Nautilus Biotechnology Inc. (NAUT) shares increased by over 7% to $1.35 [4]. - ProQR Therapeutics N.V. (PRQR) shares were up over 7% at $2.92 [4]. - Tyra Biosciences Inc. (TYRA) shares increased by over 7% to $15.00 [4]. - Imunon Inc. (IMNN) shares rose over 4% to $4.90 [4].

Accessibility StatementSkip Navigation – Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT – SAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Thursday, October 23, 2025 at 1:30 p.m. Pacific Time to provide topline results from the registrational ChonDRA ...